{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Participants who developed plasma EBV-DNA of \\>1000 copies/mL on any tests received rituximab.\n\nIncidence of Rituximab Response: Reactivated EBV participants whose plasma titers cleared after rituximab, without post-transplant lymphoproliferative disorder (PTLD).","groups":[{"description":"Visilizumab, Tacrolimus and Methotrexate. All participants.","id":"OG000","title":"First Study Stage: Study Treatment"}],"paramType":"NUMBER","populationDescription":"Reactivated EBV participants","reportingStatus":"POSTED","timeFrame":"100 days","title":"Incidence of Rituximab Response to Reactivated EBV Without PTLD","type":"SECONDARY","unitOfMeasure":"participants"}